Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets.

Alzheimer Disease / drug therapy Animals Disease Models, Animal Drug Development Genetic Predisposition to Disease Genetic Variation Humans Mice Mice, Transgenic Molecular Targeted Therapy Risk Translational Research, Biomedical

Journal

Science (New York, N.Y.)

ISSN: 1095-9203

Titre abrégé: Science

Pays: United States

ID NLM: 0404511

Informations de publication

Date de publication:
02 10 2020

Historique:

entrez: 2 10 2020

pubmed: 3 10 2020

medline: 5 11 2020

Statut: ppublish

Résumé

To provide better prevention and treatment, we need to understand the environmental and genetic risks of Alzheimer's disease (AD). However, the definition of AD has been confounded with dementia in many studies. Thus, overinterpretation of genetic findings with regard to mechanisms and drug targets may explain, in part, controversies in the field. Here, we analyze the different forms of genetic risk of AD and how these can be used to model disease. We stress the importance of studying gene variants in the right cell types and in the right pathological context. The lack of mechanistic understanding of genetic variation has become the major bottleneck in the search for new drug targets for AD.

Identifiants

DOI: 10.1126/science.abb8575 PMID: 33004512

pubmed: 33004512

pii: 370/6512/61

doi: 10.1126/science.abb8575

doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng